Condition: Diabetes Mellitus, Type 1 · Impaired Hypoglycemic Awareness · Severe Hypoglycemia · Sponsor: Vertex Pharmaceuticals Incorporated
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
This description comes directly from the study's public registry record.
Medical Information · 617-341-6777 · medicalinfo@vrtx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| UHealth Diabetes Research Institute | Miami, Florida, United States | Recruiting |
| Northwestern Organ Transplant Center | Chicago, Illinois, United States | Completed |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center Montefiore | Pittsburgh, Pennsylvania, United States | Recruiting |
| Baylor Scott and White Research Institute | Dallas, Texas, United States | Recruiting |
| VCU Medical Center, Richmond | Richmond, Virginia, United States | Recruiting |
| University of Wisconsin | Madison, Wisconsin, United States | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04786262